Helogen Announces October Missions to Advance Commercial Manufacturing in Orbit and Establish First Regulatory Pathway
The company continues to expand orbital manufacturing and names commercial customers for upcoming missions targeting GMP and FDA process initiation
LOS ANGELES, September 01, 2026--Helogen, the company building autonomous factories in space for advanced material production, today announced two missions scheduled for October 2026. The missions will support the manufacturing of biomaterials for artificial retinas and orthopedic applications, while advancing the company's work toward GMP-compliant production and FDA review.
Some of the most advanced materials used in modern medicine are built at a microscopic scale where small changes in the manufacturing environment can change the final product On Earth, gravity drives mechanical forces that can limit how cells, proteins, and other biological structures organize as they grow. In space, those forces are dramatically reduced, creating conditions for materials to form in ways that are difficult or impossible to reproduce on Earth. Biology also behaves differently in space, from accelerated aging and altered gene expression to changes in cell growth and tissue formation. Together, these effects create new ways to improve the performance, quality, and potential of bio-derived products made for use on Earth. Major advances in manufacturing have often come from finding fundamentally new ways to make things. Space is one of those new ways.
Helogen's HEL-IOS platform turns these advantages into repeatable biomanufacturing in orbit. The autonomous factory brings the core steps of terrestrial precision biomanufacturing into a closed-loop orbital system, including cell and tissue cultivation, media and fluid management, environmental control, processing, separation, harvest, and in-process quality monitoring. CELS, Helogen's NASA TechLeap Prize-winning autonomous analysis system, provides real-time characterization through imaging, spectroscopy, and sequencing. Together, these systems allow biological production to be monitored and controlled from start to finish with little to no human intervention from the ground.
The October missions mark the beginning of Helogen's regulatory path for biomaterials manufactured in space. The company will use the flights to demonstrate that its orbital manufacturing process can meet, and ultimately exceed, the requirements expected of terrestrial GMP production, including bioburden control, material recovery, process consistency, traceability, and documented quality systems. In parallel, the company is beginning the work required for FDA oversight and eventual clearance of Helogen's own proprietary materials manufactured on the platform. Data from these missions will help establish the testing, documentation, and quality standards needed to bring space-manufactured biomaterials into regulated human use.